Guiliang Chen

Dr. Guiliang Chen

Shanghai Center for Drug evaluation and Inspection

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2022 in Molecules
Verified
Journal Article
Open access
PDF file
Peng LiuPeng Liu
Peng Liu
GCGuiliang Chen
Guiliang Chen
JZJingchen Zhang
Jingchen Zhang
Liposomes have been considered promising and versatile drug vesicles. Compared with traditional drug delivery systems, liposomes exhibit better properties, including site-targeting, sustained or controlled release, protection of drugs from degradation and clearance, superior therapeutic effects, and lower toxic side effects. Given these merits, several liposomal drug products have been successfully approved and used in clinics over the last couple of decades. In this review, the liposomal drug products approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) are discussed. Based on the published approval package in the FDA and European public assessment report (EPAR) in EMA, the critical chemistry information and mature pharmaceutical technologies applied in the marketed liposomal products, including the lipid excipient, manufacturing methods, nanosizing technique, drug loading methods, as well as critical quality attributions (CQAs) of products, are introduced. Additionally, the current regulatory guidance and future perspectives related to liposomal products are summarized. This knowledge can be used for research and development of the liposomal drug candidates under various pipelines, including the laboratory bench, pilot plant, and commercial manufacturing.

11 July 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
YGYuanyuan Ge
Yuanyuan Ge
XXXingying Xu
Xingying Xu
MCMeng Cao
Meng Cao
BLBaijun Liu
Baijun Liu
YWYing Wang
Ying Wang
GCGuiliang Chen
Guiliang Chen
Nasal administration is a non-invasive method of drug delivery that offers several advantages, including rapid onset of action, ease of use, no first-pass effect, and fewer side effects. On this basis, nose-to-brain delivery technology offers a new method for drug delivery to the brain and central nervous system, which has attracted widespread attention. In this paper, the development status and trends of nasal drug delivery and nose-to-brain delivery technology are deeply analyzed through multiple dimensions: literature research, questionnaire surveys, and patent analysis. First, FDA-approved nasal formulations for nose-to-brain delivery were combed. Second, we collected a large amount of relevant information about nasal drug delivery through a questionnaire survey of 165 pharmaceutical industry practitioners in 28 provinces and 161 different organizations in China. Third, and most importantly, we conducted a patent analysis of approximately 700+ patents related to nose-to-brain delivery, both domestically and internationally. This analysis was conducted in terms of patent application trends, technology life cycle, technology composition, and technology evolution. The LDA topic model was employed to identify technological topics in each time window (1990–2023), and the five key major evolution paths were extracted. The research results in this paper will provide useful references for relevant researchers and enterprises in the pharmaceutical industry, promoting the further development and application of nasal drug delivery and nose-to-brain delivery technology.

26 March 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
QWQiwei Wang
Qiwei Wang
XLXing Ling
Xing Ling
ZDZhengli Dai
Zhengli Dai
XWXiaoling Wang
Xiaoling Wang
WGWen Guo
Wen Guo
GCGuiliang Chen
Guiliang Chen
Background: The accessibility of pediatric medicine is a global challenge. The issuance of the “Several Opinions on Ensuring the Use of Children’s Medicine” by six ministries in China in 2014 marked the formation of the policy framework. This study aims to systematically review the progress and achievements of incentive policies for China’s pediatric medicine.Methods: By analyzing policy documents, clinical trial data, review and approval results, medical insurance directories, volume-based procurement data, as well as adverse reaction reports, the implementation effects of incentive policies for China’s pediatric medicine were assessed.Results: China has made progress in legislation, research and development, review and approval, production, access, payment, and use of pediatric medicine. The number and variety of pediatric clinical trials have increased year by year. Some medicine on the Encouraged Research and Submission List of Pediatric Medicine have successfully entered the market. Priority review and approval policies have effectively facilitated the rapid approval of pediatric medicine. However, the availability still needs to be improved, especially in the field of medicine for young children (<6 years).Conclusion: Although incentive policies for China’s pediatric medicine have achieved favorable effects, the synergy of the policies still needs to be strengthened. It is recommended that the Chinese government place greater emphasis on the introduction of mandatory regulations and incentive policies, enhance the synergy between policies, use a combination of fiscal and medical insurance tools and follow up on the application of new technologies to comprehensively improve the accessibility of pediatric medicine in the future. This might be helpful for guaranteeing the safety, efficacy and economy of pediatric medicine.


22 July 2023 in Bio-Design and Manufacturing
Verified
Journal Article
Closed access
PDF file
YGYuanyuan Ge
Yuanyuan Ge
MCMeng Cao
Meng Cao
HCHui Cao
Hui Cao
BHBin Han
Bin Han
JZJingchen Zhang
Jingchen Zhang
GCGuiliang Chen
Guiliang Chen